Over 12 weeks, dosages may be titrated to 1.8 mg for liraglutide or 1 mg for semaglutide, based on clinical response, such as reduced limb volume and improved lymphatic function.55 By directly activating GLP-1 receptors on LECs, this approach stimulates lymphatic vessel repair and enhances lymphatic pumping, addressing the core pathology of lymphedema.55 Combining this treatment with conventional therapies, such as compression and physical exercise, can optimize outcomes. The gene discussed is GLP1R; the disease is lymphedema.